Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2

Agarwal, 2010, Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux, J. Pharm. Exp. Ther., 334, 147, 10.1124/jpet.110.167601 Alam, 2019, Structural insight into substrate and inhibitor discrimination by human P-glycoprotein, Science, 363, 753, 10.1126/science.aav7102 Alam, 2023, Structure and mechanism of human ABC transporters, Annu Rev. Biophys., 52, 275, 10.1146/annurev-biophys-111622-091232 Allen, 2002, Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C, Mol. Cancer Ther., 1, 417 Allikmets, 1998, A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance, Cancer Res, 58, 5337 Amawi, 2019, ABC transporter-mediated multidrug-resistant cancer, Adv. Exp. Med Biol., 1141, 549, 10.1007/978-981-13-7647-4_12 Asakura, 2004, Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats, Eur. J. Pharm., 484, 333, 10.1016/j.ejphar.2003.11.035 Bell, 1985, Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance, J. Clin. Oncol., 3, 311, 10.1200/JCO.1985.3.3.311 Bender, 2017, A computational study of the inhibition mechanisms of P-glycoprotein mediated paclitaxel efflux by kinase inhibitors, BMC Syst. Biol., 11, 108, 10.1186/s12918-017-0498-x Beretta, 2017, Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents, Eur. J. Med. Chem., 142, 271, 10.1016/j.ejmech.2017.07.062 Bhullar, 2013, The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions, PLoS One, 8, 10.1371/journal.pone.0071266 Bodo, 2003, The role of multidrug transporters in drug availability, metabolism and toxicity, Toxicol. Lett., 140–141, 133, 10.1016/S0378-4274(02)00497-6 Boesch, 1991, In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833, Cancer Res, 51, 4226 Boichuk, 2022, Infigratinib (BGJ 398), a pan-FGFR inhibitor, targets P-glycoprotein and increases chemotherapeutic-induced mortality of multidrug-resistant tumor cells, Biomedicines, 10, 10.3390/biomedicines10030601 Brendel, 2007, Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells, Leukemia, 21, 1267, 10.1038/sj.leu.2404638 Brozik, 2011, Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?, Expert Opin. Drug Metab. Toxicol., 7, 623, 10.1517/17425255.2011.562892 Cameron, 2014, Ibrutinib: first global approval, Drugs, 74, 263, 10.1007/s40265-014-0178-8 Cascorbi, 2006, Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs, Pharmacol. Ther., 112, 457, 10.1016/j.pharmthera.2006.04.009 Cermakova, 2022, Bruton's tyrosine kinase inhibitor zanubrutinib effectively modulates cancer resistance by inhibiting anthracycline metabolism and efflux, Pharmaceutics, 14, 10.3390/pharmaceutics14101994 Chan, 1996, Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation, Clin. Cancer Res, 2, 1499 Chen, 2016, Osimertinib (AZD9291) enhanced the efficacy of chemotherapeutic agents in ABCB1- and ABCG2-overexpressing cells in vitro, in vivo, and ex vivo, Mol. Cancer Ther., 15, 1845, 10.1158/1535-7163.MCT-15-0939 Chi, 2005, A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer, Invest N. Drugs, 23, 311, 10.1007/s10637-005-1439-x Cripe, 2010, Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999, Blood, 116, 4077, 10.1182/blood-2010-04-277269 Dai, 2008, Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2, Cancer Res, 68, 7905, 10.1158/0008-5472.CAN-08-0499 Damle, 1994, Dipyridamole modulates multidrug resistance and intracellular as well as nuclear levels of doxorubicin in B16 melanoma cells, Int J. Cancer, 56, 113, 10.1002/ijc.2910560120 Dancey, 2006, Strategies for optimizing combinations of molecularly targeted anticancer agents, Nat. Rev., 5, 649 Dano, 1973, Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells, Biochim. Et. Biophys. Acta, 323, 466, 10.1016/0005-2736(73)90191-0 Dantzig, 1999, Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities, J. Pharm. Exp. Ther., 290, 854 Dean, 2001, The human ATP-binding cassette (ABC) transporter superfamily, Genome Res, 11, 1156, 10.1101/gr.184901 Dey, 1997, Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein, Proc. Natl. Acad. Sci. USA, 94, 10594, 10.1073/pnas.94.20.10594 Ding, 2011, The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter, PLoS One, 6, 10.1371/journal.pone.0019329 Dohse, 2010, Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib, Drug Metab. Dispos., 38, 1371, 10.1124/dmd.109.031302 Dong, 2020, Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update, Drug Resist Updat, 49, 10.1016/j.drup.2020.100681 Dorner, 2009, Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier, J. Med Chem., 52, 6073, 10.1021/jm900940f Doyle, 1998, A multidrug resistance transporter from human MCF-7 breast cancer cells, Proc. Natl. Acad. Sci. USA, 95, 15665, 10.1073/pnas.95.26.15665 Draper, 1997, Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein, Br. J. Cancer, 75, 810, 10.1038/bjc.1997.145 Drewe, 1999, HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833, Biochem Pharm., 57, 1147, 10.1016/S0006-2952(99)00026-X Duran, 2019, The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance, PLoS One, 14, 10.1371/journal.pone.0210879 Elahian, 2010, Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines, Drug Chem. Toxicol., 33, 113, 10.3109/01480540903390000 Elia, 2022, Loperamide potentiates doxorubicin sensitivity in triple-negative breast cancer cells by targeting MDR1 and JNK and suppressing mTOR and Bcl-2: In vitro and molecular docking study, J. Biochem. Mol. Toxicol., 36, 10.1002/jbt.22938 Endo, 2010, A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts, Cancer Chemother. Pharm., 65, 363, 10.1007/s00280-009-1042-5 Englinger, 2016, Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression, Oncotarget, 7, 50161, 10.18632/oncotarget.10324 Eriksson, 2006, Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion, Drug Metab. Dispos., 34, 775, 10.1124/dmd.105.008607 Fan, 2022, Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo, Mol. Ther. Oncolytics, 24, 636, 10.1016/j.omto.2022.02.006 Fan, 2018, Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters, Cancer Lett., 421, 186, 10.1016/j.canlet.2018.01.021 Feng, 2020, Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells, Front Oncol., 10, 955, 10.3389/fonc.2020.00955 Ferry, 1996, Clinical trials of P-glycoprotein reversal in solid tumours, Eur. J. Cancer, 32A, 1070, 10.1016/0959-8049(96)00091-3 Fischer, 1998, The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite, Drug Metab. Dispos., 26, 802 Fox, 2015, Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors, Cancer Chemother. Pharm., 76, 1273, 10.1007/s00280-015-2845-1 Friedenberg, 2006, Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group, Cancer, 106, 830, 10.1002/cncr.21666 Germann, 1997, Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP, Anticancer Drugs, 8, 141, 10.1097/00001813-199702000-00005 Giaccone, 1996, Drug Resistance, Oncologist, 1, 82, 10.1634/theoncologist.1-1-82 Gillet, 2010, Mechanisms of multidrug resistance in cancer, Methods Mol. Biol., 596, 47, 10.1007/978-1-60761-416-6_4 Gottesman, 2002, Mechanisms of cancer drug resistance, Annu. Rev. Med., 53, 615, 10.1146/annurev.med.53.082901.103929 Gottesman, 2002, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat. Rev. Cancer, 2, 48, 10.1038/nrc706 Greenberg, 2004, Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995), J. Clin. Oncol., 22, 1078, 10.1200/JCO.2004.07.048 Gupta, 2007, Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP), J. Pharm. Sci., 96, 3226, 10.1002/jps.20963 Gupta, 2004, HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2), J. Pharm. Exp. Ther., 310, 334, 10.1124/jpet.104.065342 Habeck, 2002, FDA licences imatinib mesylate for CML, Lancet Oncol., 3, 6, 10.1016/S1470-2045(01)00608-8 Hegedus, 2009, Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties, Br. J. Pharm., 158, 1153, 10.1111/j.1476-5381.2009.00383.x Houghton, 2004, Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro, Cancer Res, 64, 2333, 10.1158/0008-5472.CAN-03-3344 Hsiao, 2016, Osimertinib (AZD9291) attenuates the function of multidrug resistance-linked ATP-binding cassette transporter ABCB1 in Vitro, Mol. Pharm., 13, 2117, 10.1021/acs.molpharmaceut.6b00249 Hsiao, 2019, The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents, Cancer Lett., 445, 34, 10.1016/j.canlet.2019.01.001 Hu, 2015, Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo, Oncotarget, 6, 44643, 10.18632/oncotarget.5989 Hu, 2009, Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters, Clin. Cancer Res, 15, 6062, 10.1158/1078-0432.CCR-09-0048 Huang, 2016, Simotinib as a modulator of P-glycoprotein: substrate, inhibitor, or inducer?, Anticancer Drugs, 27, 300, 10.1097/CAD.0000000000000332 Huang, 2022, Terfenadine resensitizes doxorubicin activity in drug-resistant ovarian cancer cells via an inhibition of CaMKII/CREB1 mediated ABCB1 expression, Front Oncol., 12, 10.3389/fonc.2022.1068443 Ibrahim, 2022, Exploring natural product activity and species source candidates for hunting abcb1 transporter inhibitors: an in silico drug discovery study, Molecules, 27, 10.3390/molecules27103104 Ibrahim, 2021, Prospective drug candidates as human multidrug transporter abcg2 inhibitors: an in silico drug discovery study, Cell Biochem Biophys., 79, 189, 10.1007/s12013-021-00985-y Jackson, 2018, Structural basis of small-molecule inhibition of human multidrug transporter ABCG2, Nat. Struct. Mol. Biol., 25, 333, 10.1038/s41594-018-0049-1 Ji, 2019, Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells, Cancer Lett. 440-, 441, 82, 10.1016/j.canlet.2018.10.007 Ji, 2019, Midostaurin Reverses ABCB1-mediated multidrug resistance, an in vitro study, Front Oncol., 9, 514, 10.3389/fonc.2019.00514 Jing, 2021, In vitro and ex vivo anti‑tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2–overexpressing leukemia cells, Oncol. Rep., 45, 1142, 10.3892/or.2020.7915 Jones, 1990, A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer, Br. J. Cancer, 62, 133, 10.1038/bjc.1990.244 Jonsson, 1999, Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity, Biochem Pharm., 58, 1801, 10.1016/S0006-2952(99)00262-2 Juliano, 1976, A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochim. Et. Biophys. Acta, 455, 152, 10.1016/0005-2736(76)90160-7 Kartner, 1983, Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines, Science, 221, 1285, 10.1126/science.6137059 Kelly, 2011, A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer, Clin. Cancer Res, 17, 569, 10.1158/1078-0432.CCR-10-1725 Kerklaan, 2015, Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours, Br. J. Cancer, 113, 706, 10.1038/bjc.2015.257 Kessel, 1968, Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response, Cancer Res, 28, 938 Kim, 2011, Metformin inhibits P-glycoprotein expression via the NF-kappaB pathway and CRE transcriptional activity through AMPK activation, Br. J. Pharm., 162, 1096, 10.1111/j.1476-5381.2010.01101.x Kim, 2019, Histamine receptor antagonists, loratadine and azelastine, sensitize p-gp-overexpressing antimitotic drug-resistant KBV20C cells through different molecular mechanisms, Anticancer Res., 39, 3767, 10.21873/anticanres.13525 Kitazaki, 2005, Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells, Lung Cancer, 49, 337, 10.1016/j.lungcan.2005.03.035 Kort, 2015, Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1), Pharm. Res, 32, 2205, 10.1007/s11095-014-1609-7 Kosloski, 2019, Translation of in vitro transport inhibition studies to clinical drug-drug interactions for glecaprevir and pibrentasvir, J. Pharm. Exp. Ther., 370, 278, 10.1124/jpet.119.256966 Kovalev, 2013, Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer, Exp. Oncol., 35, 287 Kowal, 2021, Structural basis of drug recognition by the multidrug transporter ABCG2, J. Mol. Biol., 433, 10.1016/j.jmb.2021.166980 Kruijtzer, 2002, Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918, J. Clin. Oncol., 20, 2943, 10.1200/JCO.2002.12.116 Kuhnle, 2009, Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar, J. Med Chem., 52, 1190, 10.1021/jm8013822 Kukal, 2021, Multidrug efflux transporter ABCG2: expression and regulation, Cell Mol. Life Sci., 78, 6887, 10.1007/s00018-021-03901-y Lage, 2016, Gene therapeutic approaches to overcome ABCB1-mediated drug resistance, Recent Results Cancer Res, 209, 87, 10.1007/978-3-319-42934-2_6 Le, 2021, Structure-based discovery of ABCG2 inhibitors: a homology protein-based pharmacophore modeling and molecular docking approach, Molecules, 26, 10.3390/molecules26113115 Leggas, 2006, Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo, Cancer Res, 66, 4802, 10.1158/0008-5472.CAN-05-2915 Lhomme, 2008, Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer, J. Clin. Oncol., 26, 2674, 10.1200/JCO.2007.14.9807 Li, 2016, Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies, Drug Resist Updat, 27, 14, 10.1016/j.drup.2016.05.001 Libby, 2010, Dismounting the MDR horse, Blood, 116, 4037, 10.1182/blood-2010-09-304311 Limniatis, 2021, The phenothiazine, trifluoperazine, is selectively lethal to ABCB1-expressing multidrug resistant cells, Biochem. Biophys. Res. Commun., 570, 148, 10.1016/j.bbrc.2021.07.031 Lin, 2013, Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo, Eur. J. Cancer, 49, 2059, 10.1016/j.ejca.2012.12.028 List, 2001, Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a southwest oncology group study, Blood, 98, 3212, 10.1182/blood.V98.12.3212 List, 1993, Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia, J. Clin. Oncol., 11, 1652, 10.1200/JCO.1993.11.9.1652 Litman, 2000, The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2), J. Cell Sci., 113, 2011, 10.1242/jcs.113.11.2011 Liu, 2011, Tamoxifen reverses the multi-drug-resistance of an established human cholangiocarcinoma cell line in combined chemotherapeutics, Mol. Biol. Rep., 38, 1769, 10.1007/s11033-010-0291-z Manolaridis, 2018, Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states, Nature, 563, 426, 10.1038/s41586-018-0680-3 Marchetti, 2008, Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice, Mol. Cancer Ther., 7, 2280, 10.1158/1535-7163.MCT-07-2250 Markowicz-Piasecka, 2021, Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP), Int. J. Mol. Sci., 22, 10.3390/ijms22147727 Martin, 1999, The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein, Br. J. Pharm., 128, 403, 10.1038/sj.bjp.0702807 Matthews, 2006, MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia, Leuk. Lymphoma, 47, 2308, 10.1080/10428190600881421 Mesgari Abbasi, 2016, The Effects of Cetirizine on P-glycoprotein expression and function in vitro and in situ, Adv. Pharm. Bull., 6, 111, 10.15171/apb.2016.017 Mi, 2007, ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein, Br. J. Cancer, 97, 934, 10.1038/sj.bjc.6603985 Mi, 2010, Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters, Cancer Res, 70, 7981, 10.1158/0008-5472.CAN-10-0111 Minami, 2012, HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer, Mol. Cancer Ther., 11, 830, 10.1158/1535-7163.MCT-11-0884 Minocha, 2012, Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors, Int J. Pharm., 434, 306, 10.1016/j.ijpharm.2012.05.028 Mistry, 2001, In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576, Cancer Res, 61, 749 Miyake, 1999, Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes, Cancer Res, 59, 8 Miyata, 2016, Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations, Front. Pharmacol., 7, 518, 10.3389/fphar.2016.00518 Moinul, 2022, Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development, Eur. J. Med. Chem., 241, 10.1016/j.ejmech.2022.114628 Mora Lagares, 2022, Recent advances on P-glycoprotein (ABCB1) transporter modelling with in silico methods, Int. J. Mol. Sci., 23, 10.3390/ijms232314804 Noguchi, 2014, Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics, Pharm. Pers. Med., 7, 53 Noguchi, 2009, Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib, Cancer Sci., 100, 1701, 10.1111/j.1349-7006.2009.01213.x Nosol, 2020, Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1, Proc. Natl. Acad. Sci. USA, 117, 26245, 10.1073/pnas.2010264117 Oh, 2022, Co-treatment of low dose pacritinib, a phase III Jak2 inhibitor, greatly increases apoptosis of P-gp over-expressing cancer cells with multidrug resistance, Anticancer Res., 42, 2433, 10.21873/anticanres.15722 Oh, 2022, JAK2 inhibitor, fedratinib, inhibits P-gp activity and co-treatment induces cytotoxicity in antimitotic drug-treated P-gp overexpressing resistant KBV20C cancer cells, Int. J. Mol. Sci., 23, 10.3390/ijms23094597 Oldham, 1998, A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer, Cancer Biother Radio., 13, 71 Orlando, 2020, ABCG2 transports anticancer drugs via a closed-to-open switch, Nat. Commun., 11, 2264, 10.1038/s41467-020-16155-2 Ouwerkerk-Mahadevan, 2016, Drug-DRUG INTERACTIONS WIth the NS3/4A protease inhibitor simeprevir, Clin. Pharm., 55, 197, 10.1007/s40262-015-0314-y Ozvegy-Laczka, 2005, Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters, Drug Resist Updat, 8, 15, 10.1016/j.drup.2005.02.002 Ozvegy-Laczka, 2004, High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter, Mol. Pharm., 65, 1485, 10.1124/mol.65.6.1485 Ozvegy, 2001, Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells, Biochem. Biophys. Res. Commun., 285, 111, 10.1006/bbrc.2001.5130 Palmeira, 2011, New uses for old drugs: pharmacophore-based screening for the discovery of P-glycoprotein inhibitors, Chem. Biol. Drug Des., 78, 57, 10.1111/j.1747-0285.2011.01089.x Palmeira, 2012, Three decades of P-gp inhibitors: skimming through several generations and scaffolds, Curr. Med. Chem., 19, 1946, 10.2174/092986712800167392 Parvathaneni, 2019, Drug repurposing: a promising tool to accelerate the drug discovery process, Drug Discov. Today, 24, 2076, 10.1016/j.drudis.2019.06.014 Patch, 2015, Whole-genome characterization of chemoresistant ovarian cancer, 521, 489 Pawarode, 2007, Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins, Cancer Chemother. Pharm., 60, 179, 10.1007/s00280-006-0357-8 Pena-Solorzano, 2017, ABCG2/BCRP: specific and nonspecific modulators, Med. Res. Rev., 37, 987, 10.1002/med.21428 Pillaiyar, 2020, A medicinal chemistry perspective of drug repositioning: recent advances and challenges in drug discovery, Eur. J. Med. Chem., 195, 10.1016/j.ejmech.2020.112275 Pluchino, 2012, Collateral sensitivity as a strategy against cancer multidrug resistance, Drug Resist Updat, 15, 98, 10.1016/j.drup.2012.03.002 Pushpakom, 2019, Drug repurposing: progress, challenges and recommendations, Nat. Rev., 18, 41 Qiu, 2015, Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter, Oncotarget, 6, 15494, 10.18632/oncotarget.3820 Rabindran, 2000, Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein, Cancer Res, 60, 47 Ramos-Penafiel, 2018, Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene, J. Transl. Med, 16, 245, 10.1186/s12967-018-1620-6 Rijpma, 2014, Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity, Malar. J., 13, 359, 10.1186/1475-2875-13-359 Robey, 2018, Revisiting the role of ABC transporters in multidrug-resistant cancer, Nat. Rev. Cancer, 18, 452, 10.1038/s41568-018-0005-8 Robey, 2007, Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure, Mol. Cancer Ther., 6, 1877, 10.1158/1535-7163.MCT-06-0811 Ross, 2000, Expression of breast cancer resistance protein in blast cells from patients with acute leukemia, Blood, 96, 365, 10.1182/blood.V96.1.365 Sabet, 2022, Talazoparib does not interact with ABCB1 transporter or cytochrome P450s, but modulates multidrug resistance mediated by ABCC1 and ABCG2: an in vitro and ex vivo study, Int. J. Mol. Sci., 23, 10.3390/ijms232214338 Schwarzenbach, 2002, Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma, Med. Oncol., 19, 87, 10.1385/MO:19:2:87 Seelig, 2023, P-glycoprotein (ABCB1) - weak dipolar interactions provide the key to understanding allocrite recognition, binding, and transport, Cancer Drug Resist, 6, 1, 10.20517/cdr.2022.59 Sen, 2012, The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2, Mol. Cancer Ther., 11, 2033, 10.1158/1535-7163.MCT-12-0302 Senarathna, 2016, The interactions of p-glycoprotein with antimalarial drugs, including substrate affinity, inhibition and regulation, PLoS One, 11, 10.1371/journal.pone.0152677 Shepard, 2003, Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979, Int J. Cancer, 103, 121, 10.1002/ijc.10792 Shi, 2007, Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance, Cancer Res, 67, 11012, 10.1158/0008-5472.CAN-07-2686 Shi, 2011, Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance, Cancer Res, 71, 3029, 10.1158/0008-5472.CAN-10-3820 Shiraki, 2002, Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells, Jpn J. Cancer Res, 93, 209, 10.1111/j.1349-7006.2002.tb01260.x Shukla, 2009, Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2, Drug Metab. Dispos., 37, 359, 10.1124/dmd.108.024612 Sims, 2013, Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-kappaB and HSP27/p38/AKT pathways and by inhibiting ABCB1, PLoS One, 8, 10.1371/journal.pone.0055509 Smith, 1998, Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum, J. Natl. Cancer Inst., 90, 1161, 10.1093/jnci/90.15.1161 Sorf, 2022, Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy, Toxicol. Appl. Pharm., 434, 10.1016/j.taap.2021.115797 Steinbach, 2002, BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia, Leukemia, 16, 1443, 10.1038/sj.leu.2402541 Su, 2021, Novel nanomedicines to overcome cancer multidrug resistance, Drug Resist Updat, 58, 10.1016/j.drup.2021.100777 Sun, 2012, Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance, Anticancer Drugs, 23, 865, 10.1097/CAD.0b013e328354a196 Takara, 2009, Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport, Oncol. Res, 17, 527, 10.3727/096504009789745601 Tao, 2009, Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function, Cancer Chemother. Pharm., 64, 961, 10.1007/s00280-009-0949-1 Taylor, 2017, Structure of the human multidrug transporter ABCG2, Nature, 546, 504, 10.1038/nature22345 Tiwari, 2013, Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models, Cancer Lett., 328, 307, 10.1016/j.canlet.2012.10.001 Tiwari, 2009, Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters, Biochem Pharm., 78, 153, 10.1016/j.bcp.2009.04.002 Tournier, 2017, Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates, J. Nucl. Med, 58, 117, 10.2967/jnumed.116.178665 Traxl, 2015, Breast cancer resistance protein and p-glycoprotein influence in vivo disposition of 11C-erlotinib, J. Nucl. Med, 56, 1930, 10.2967/jnumed.115.161273 Tsuruo, 1981, Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil, Cancer Res, 41, 1967 Tsuruo, 1981, Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil, Cancer Res, 41, 1967 Turner, 2006, ABCG2 expression, function, and promoter methylation in human multiple myeloma, Blood, 108, 3881, 10.1182/blood-2005-10-009084 Twentyman, 1987, Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line, Br. J. Cancer, 56, 55, 10.1038/bjc.1987.153 Uggla, 2005, BCRP mRNA expression v. clinical outcome in 40 adult AML patients, Leuk. Res, 29, 141, 10.1016/j.leukres.2004.06.004 Urgaonkar, 2022, Discovery and characterization of potent dual P-glycoprotein and CYP3A4 inhibitors: design, synthesis, Cryo-EM analysis, and biological evaluations, J. Med Chem., 65, 191, 10.1021/acs.jmedchem.1c01272 Vagiannis, 2020, Ensartinib (X-396) effectively modulates pharmacokinetic resistance mediated by ABCB1 and ABCG2 drug efflux transporters and CYP3A4 biotransformation enzyme, Cancers, 12, 10.3390/cancers12040813 Vagiannis, 2020, Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme, Biochem Pharm., 178, 10.1016/j.bcp.2020.114061 van den Heuvel-Eibrink, 2002, Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML), Leukemia, 16, 833, 10.1038/sj.leu.2402496 van Hoppe, 2018, P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability, Mol. Pharm., 15, 5124, 10.1021/acs.molpharmaceut.8b00702 van Zuylen, 2000, The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel, Clin. Cancer Res, 6, 1365 Varma, 2003, P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement, Pharm. Res, 48, 347, 10.1016/S1043-6618(03)00158-0 Volk, 2000, Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux, Cancer Res, 60, 3514 Wang, 2014, Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2, Oncotarget, 5, 4529, 10.18632/oncotarget.2102 Wang, 2001, The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein, Cancer Res, 61, 7525 Wang, 2015, Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells, Oncotarget, 6, 40850, 10.18632/oncotarget.5813 Wang, 2012, Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2, Mol. Med, 18, 887, 10.2119/molmed.2011.00444 Wang, 2021, Anlotinib reverses multidrug resistance (MDR) in osteosarcoma by inhibiting p-glycoprotein (PGP1) function in vitro and in vivo, Front. Pharmacol., 12 Wang, 2020, Venetoclax, a BCL-2 inhibitor, enhances the efficacy of chemotherapeutic agents in wild-type ABCG2-overexpression-mediated MDR cancer cells, Cancers, 12 Wang, 2008, Antipsychotic drugs inhibit the function of breast cancer resistance protein, Basic Clin. Pharm. Toxicol., 103, 336, 10.1111/j.1742-7843.2008.00298.x Wang, 2014, Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo, Oncotarget, 5, 11971, 10.18632/oncotarget.2647 Wang, 2017, Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study, Cancer Lett., 396, 145, 10.1016/j.canlet.2017.03.011 Weidner, 2015, The Inhibitor Ko143 Is Not Specific for ABCG2, J. Pharm. Exp. Ther., 354, 384, 10.1124/jpet.115.225482 Weiss, 2014, Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro, Int J. Antimicrob. Agents, 43, 184, 10.1016/j.ijantimicag.2013.10.003 Weiss, 2007, Modulation of human BCRP (ABCG2) activity by anti-HIV drugs, J. Antimicrob. Chemother., 59, 238, 10.1093/jac/dkl474 Westover, 2015, FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance, Mol. Cancer, 14, 92, 10.1186/s12943-015-0362-9 Wilson, 2006, Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction, Blood, 108, 685, 10.1182/blood-2004-12-4633 Wu, 2008, Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies, Curr. Mol. Pharmacol., 1, 93, 10.2174/1874467210801020093 Wu, 2020, Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs, Cancers, 12 Wu, 2014, Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1, Mol. Pharm., 11, 3727, 10.1021/mp500492r Wu, 2013, Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1, Biochem Pharm., 86, 904, 10.1016/j.bcp.2013.08.004 Wu, 2015, Human ATP-binding cassette transporter ABCB1 confers resistance to volasertib (BI 6727), a selective inhibitor of polo-like kinase 1, Mol. Pharm., 12, 3885, 10.1021/acs.molpharmaceut.5b00312 Wu, 2016, Human ATP-binding cassette transporter ABCG2 confers resistance to CUDC-907, a dual inhibitor of histone deacetylase and phosphatidylinositol 3-kinase, Mol. Pharm., 13, 784, 10.1021/acs.molpharmaceut.5b00687 Wu, 2018, Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines, Biochem Pharm., 155, 316, 10.1016/j.bcp.2018.07.018 Wu, 2023, ABCB1 and ABCG2 overexpression mediates resistance to the phosphatidylinositol 3-kinase inhibitor hs-173 in cancer cell lines, Cells, 12, 10.3390/cells12071056 Wu, 2021, Overexpression of human ABCB1 and ABCG2 reduces the susceptibility of cancer cells to the histone deacetylase 6-specific inhibitor citarinostat, Int. J. Mol. Sci., 22 Wu, 2020, Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines, Biochem Pharm., 180, 10.1016/j.bcp.2020.114137 Wu, 2020, Erdafitinib resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs, Cancers, 12 Wu, 2021, The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs, Biochem Pharm., 188, 10.1016/j.bcp.2021.114516 Wu, 2019, Avapritinib: a selective inhibitor of KIT and PDGFRalpha that Reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cell lines, Mol. Pharm., 16, 3040, 10.1021/acs.molpharmaceut.9b00274 Wu, 2021, Branebrutinib (BMS-986195), a bruton's tyrosine kinase inhibitor, resensitizes P-glycoprotein-overexpressing multidrug-resistant cancer cells to chemotherapeutic agents, Front. Cell Dev. Biol., 9 Wu, 2013, Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells, Biochem Pharm., 85, 325, 10.1016/j.bcp.2012.11.003 Wu, 2018, Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells, Mol. Cancer, 17, 25, 10.1186/s12943-018-0775-3 Wu, 2017, Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo, Biochem Pharm., 124, 29, 10.1016/j.bcp.2016.10.015 Wu, 2019, Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells, Biochem Pharm., 166, 120, 10.1016/j.bcp.2019.05.015 Wu, 2022, MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study, Acta Pharm. Sin. B, 12, 2609, 10.1016/j.apsb.2021.12.018 Xiang, 2011, Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance, Cell Oncol. (Dordr. ), 34, 33, 10.1007/s13402-010-0003-7 Yanagisawa, 1999, BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma, Br. J. Cancer, 80, 1190, 10.1038/sj.bjc.6990485 Yanase, 2004, Gefitinib reverses breast cancer resistance protein-mediated drug resistance, Mol. Cancer Ther., 3, 1119, 10.1158/1535-7163.1119.3.9 Yang, 2014, Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP), Future Oncol., 10, 1827, 10.2217/fon.13.253 Yang, 2017, K.K. To, F. Wang, D. Li, L. Chen and L. Fu, Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo, Exp. Mol. Med, 49, 10.1038/emm.2016.168 Yoh, 2004, Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer, Clin. Cancer Res, 10, 1691, 10.1158/1078-0432.CCR-0937-3 Yu, 2021, Structures of ABCG2 under turnover conditions reveal a key step in the drug transport mechanism, Nat. Commun., 12, 4376, 10.1038/s41467-021-24651-2 Zembruski, 2011, Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro, J. Antimicrob. Chemother., 66, 802, 10.1093/jac/dkq501 Zhang, 2017, Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib, Pharm. Res, 119, 89, 10.1016/j.phrs.2017.01.024 Zhang, 2017, The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors, Mol. Cancer Ther., 16, 1021, 10.1158/1535-7163.MCT-16-0511 Zhang, 2014, AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance, Cancer Lett., 350, 61, 10.1016/j.canlet.2014.04.008 Zhang, 2021, Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp), Med. Res. Rev., 41, 525, 10.1002/med.21739 Zhang, 2022, Ribociclib inhibits P-gp-mediated multidrug resistance in human epidermoid carcinoma cells, Front. Pharmacol., 13 Zhang, 2018, Olmutinib (BI1482694/HM61713), a novel epidermal growth factor receptor tyrosine kinase inhibitor, reverses ABCG2-mediated multidrug resistance in cancer cells, Front. Pharmacol., 9, 1097, 10.3389/fphar.2018.01097 Zhang, 2005, BCRP transports dipyridamole and is inhibited by calcium channel blockers, Pharm. Res, 22, 2023, 10.1007/s11095-005-8384-4 Zhang, 2022, Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo, Cell Commun. Signal, 20, 142, 10.1186/s12964-022-00955-8 Zhang, 2022, Sonidegib potentiates the cancer cells' sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo, Biochem Pharm., 199, 10.1016/j.bcp.2022.115009 Zhang, 2019, Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer, Cancer Lett., 442, 104, 10.1016/j.canlet.2018.10.032 Zhang, 2016, Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters, Sci. Rep., 6, 25694, 10.1038/srep25694 Zhao, 2012, Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo, Mol. Pharm., 82, 47, 10.1124/mol.111.076299 Zheng, 2009, Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function, PLoS One, 4, 10.1371/journal.pone.0005172 Zhou, 2012, Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein, Br. J. Pharm., 166, 1669, 10.1111/j.1476-5381.2012.01849.x Zhu, 2007, Risperidone and paliperidone inhibit p-glycoprotein activity in vitro, Neuropsychopharmacology, 32, 757, 10.1038/sj.npp.1301181